- Press Releases
Press Releases To List
- Notice Concerning the Establishment of Michiteku Co., Ltd.
- Ono Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
- Ono and NS Solutions Jointly Build “OASIS”, an Infrastructure for Utilizing Integrated Data
- Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Generated from the Collaboration with Fate Therapeutics
- Ono Enters a Drug Discovery Collaboration Agreement with Memo Therapeutics to Discover and Develop Antibody Drugs in the Immuno-oncology Field
Notices To List
- Announcement on posting of Corporate Report 2022
- Notifications regarding "Change of Domain" in our Website and Blocking to Receive Emails Containing "a Zip File with Password"
- Voting Results (Extraordinary Report) of the 74th Ordinary General Shareholders’ Meeting
- Notice to Resolutions Passed at The 74th Ordinary General shareholders’ Meeting
- Notice to Convene the 74th Ordinary General Shareholders’ Meeting
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.